LakeShore Biopharma Files 6-K with FY2025 Half Year Results
Ticker: LSBWF · Form: 6-K · Filed: Oct 8, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, foreign-issuer, company-name-change
TL;DR
LAKESHORE BIOPHARMA (LSPB) FILED 6-K WITH FY2025 HALF-YEAR RESULTS.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on October 8, 2024. The filing includes a press release providing their financial results for the fiscal half year ending 2025. The company is headquartered in Beijing, PRC.
Why It Matters
This filing provides investors with an update on LakeShore Biopharma's financial performance for the first half of their 2025 fiscal year, allowing for assessment of their business trajectory.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not contain significant new risks.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former company name
- YishengBio Co., Ltd (company) — Former company name
- 001-41598 (dollar_amount) — SEC file number
FAQ
What is the reporting period for the financial results mentioned in the filing?
The filing mentions a press release providing financial results for the fiscal half year ending 2025.
What is the company's current name and what were its previous names?
The company's current name is LakeShore Biopharma Co., Ltd. Its former names were YS Biopharma Co., Ltd. and YishengBio Co., Ltd.
When did the company change its name from YS Biopharma Co., Ltd.?
The date of the name change from YS Biopharma Co., Ltd. was March 10, 2023.
Where is LakeShore Biopharma Co., Ltd. headquartered?
The company is headquartered in Daxing District, Beijing, PRC.
What type of filing is this and what is its purpose?
This is a Form 6-K, which is a Report of Foreign Private Issuer, filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of October 2024.
Filing Stats: 179 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-10-08 08:59:35
Filing Documents
- ea0217042-6k_lakeshore.htm (6-K) — 14KB
- ea021704201ex99-1_lakeshore.htm (EX-99.1) — 10KB
- 0001213900-24-086088.txt ( ) — 25KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release – LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: October 8, 2024 2